Key Highlights: Implications: Nucelion and VeGen Bio’s partnership could strengthen India’s domestic CAR-T manufacturing ecosystem by combining dual-target therapy development with GMP production capabilities. VL-2511’s BCMA/CD19 approach may help address antigen escape in multiple myeloma, while localized manufacturing could improve affordability and access. Clinical validation, scalability and regulatory compliance will determine its competitive potential. Source:...
As pharmaceutical supply chains evolve, India has an opportunity to transform its reliance on imported active pharmaceutical ingredients into a new era of manufacturing leadership, scientific innovation, and global supply chain resilience. Every medicine begins with a molecule that makes treatment possible. Behind every tablet, capsule, injection, or complex therapy lies an essential component that...
As trade tensions reshape pharmaceutical supply chains, India faces a pivotal test: protecting its position as a global medicines supplier while navigating rising costs, shifting manufacturing priorities, and the risk of disrupted patient access. Medicines do not stop at borders, but the policies governing their movement increasingly do. Across the global pharmaceutical industry, tariffs have...
Executive Summary India has emerged as a major force in the global pharmaceutical industry, supported by its extensive manufacturing infrastructure, technical expertise and strong presence across international markets. Active Pharmaceutical Ingredients (APIs) remain a critical component of this ecosystem, enabling the production of medicines across a wide range of therapeutic areas. Indian manufacturers have developed...
Summary India’s pharmaceutical industry is beginning to move from a manufacturing-led model toward a more technology-driven approach to drug discovery, with AI emerging as an important part of that transition. India has already produced more than 10 novel drug assets over the past decade, while PE/VC investment in pharma increased 2.1-fold to $731 million in...
Key Highlights: Implications: Nucelion and VeGen Bio’s partnership could strengthen India’s domestic CAR-T manufacturing ecosystem by combining dual-target therapy development with GMP production capabilities. VL-2511’s BCMA/CD19 approach may help address antigen escape in multiple myeloma, while localized manufacturing could improve affordability and access. Clinical validation, scalability and regulatory compliance will determine its competitive potential. Source:...
Key Highlights: Implications: Dr. Reddy’s has secured CDSCO approval for its abatacept biosimilar (250 mg IV) for adults with moderate‑to‑severe active rheumatoid arthritis and active psoriatic arthritis who failed other DMARDs, with manufacturing at its Bachupally biologics facility and supply support from Gland Pharma. The approval is conditional on a Phase IV study (protocol due within 3...
